Scanning with robots

Knight, Helen
February 2005
Engineer (00137758);2/25/2005, Vol. 293 Issue 7669, p12
This article reports that a robot surgeon that can be attached to an MRI scanner to improve the accuracy of prostate cancer biopsies is being developed for the Great Britain National Health Service (NHS). This will allow surgeons to carry out biopsies using the much more detailed images produced by MRI scanners, rather than the fuzzy ultrasound pictures used at present, improving their accuracy. The project is being funded under the NHS Prostate Cancer Programme, which was launched in 2000, in an effort to expand research into the condition and improve treatment. INSET: ...and operating with virtual reality system.


Related Articles

  • U.K.'s efforts to improve multidisciplinary care criticized. Illman, John // JNCI: Journal of the National Cancer Institute;02/06/2002, Vol. 94 Issue 3, p163 

    Reports the criticism on the multidisciplinary cancer care program of the National Health Service in Great Britain. Purpose of the program; Consultant system of the program; Complexities in managing multidisciplinary cancer care.

  • News Brief: MRI scans on demand.  // GP: General Practitioner;5/24/2004, p21 

    Mediscan is offering a self-pay MRI scanning service for patients who do not want to wait for an appointment with Great Britain National Health Service and do not have private health insurance. The company is piloting the service in south-east Wales first. Prices start at pounds 325 for a...

  • Britain struggles to correct spending imbalances. Illman, John; Illman, J // JNCI: Journal of the National Cancer Institute;08/16/2000, Vol. 92 Issue 16, p1290 

    Reports the spending imbalances in cancer treatments by the National Health Service (NHS) in Great Britain. Consideration on the NHS as a state funded health agency; NHS compliance with the international standard of allocation practice; Comparison between the perception regarding effective...

  • Latest recommendations from UK NICE.  // PharmacoEconomics & Outcomes News;12/11/2010, Issue 618, p2 

    The article focuses on the final guidance published by the Great Britain National Institute for Health and Clinical Excellence (NICE) which recommended trastuzumab as an adjunctive option to chemotherapy among certain patients with metastatic gastric cancer.

  • Commitment to oncology.  // British Medical Journal;4/2/1977, Vol. 1 Issue 6065, p864 

    Examines the importance of medical oncology in cancer medicine in Great Britain. Effectiveness of chemotherapy on cancer treatment; Creation of medical oncology within the National Health Service; Changing patterns of cancer diagnosis and treatment.

  • One in four cancer scripts unfilled. Anekwe, Lilian // Pulse;9/14/2011, Vol. 71 Issue 29, p13 

    The article reports on the findings of the study by the British National Health Service (NHS) regarding the practice of prescribing, which found that one in four prescription for cancer drugs or immunosuppressants remains unfilled, wherein, only 73.5% of drugs were redeemed.

  • Three drugs added to England's Cancer Drugs Fund list.  // PharmacoEconomics & Outcomes News;Feb2014, Vol. 696 Issue 1, p10 

    The article reports that the National Health Service has added three drugs to England's Cancer Drugs Fund list, namely trastuzumab emtansine for breast cancer patients, radium-223 dichloride for prostate cancer patients, and dabrafenib for metastatic melanoma patients.

  • Patients at risk from old equipment, say LibDems. Conrad, Mark // Public Finance;1/16/2004-1/22/2004, p13 

    Reports that the Health ministers have dismissed Liberal Democrat claims that National Health Service patient's lives are underthreat from patch up life-saving equipment in Great Britain. Estimation of the cost of upgrading equipment to acceptable standards; Inadequacy of the provision of...

  • Kadcyla, a breast cancer drug marketed by Roche Products Limited has been turned down by the NHS drugs rationing body as it is too expensive.  // Manufacturer;Sep2014, Vol. 17 Issue 7, p10 

    The article informs that British National Health Service, a publicly funded healthcare system has turned down the breast cancer drug Kadcyla marketed by Roche Products Ltd. because of its cost and mentions the views of Andrew Dillon, National Institute for Health & Care Excellence.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics